Download PDF
Hamostaseologie 2020; 40(01): 088-096
DOI: 10.1055/s-0039-3402805
Review Article
Georg Thieme Verlag KG Stuttgart · New York

How Do I Counsel Parents of a Newly Diagnosed Boy with Haemophilia A?

Karin Kurnik
1   Paediatric Haemophilia Centre, Dr. von Hauner Children's Hospital Munich, LMU, Munich, Germany
,
Christoph Bidlingmaier
1   Paediatric Haemophilia Centre, Dr. von Hauner Children's Hospital Munich, LMU, Munich, Germany
2   Center for Development and Complex Chronic Diseases in Children (iSPZ Hauner), Munich, Germany
,
Martin Olivieri
1   Paediatric Haemophilia Centre, Dr. von Hauner Children's Hospital Munich, LMU, Munich, Germany
› Author Affiliations
Further Information

Publication History

31 July 2019

04 November 2019

Publication Date:
28 January 2020 (online)

Also available at
   Permissions and Reprints

Abstract

With the recent approval of improved therapeutic options for patients suffering from haemophilia A such as the extended half-life, recombinant factor concentrates, non-factor VIII replacement therapies like Emicizumab and after consideration of the currently running clinical trials investigating even more advanced approaches, counselling of parents of a newly diagnosed boy with haemophilia A has not become less demanding. Parents need to be informed about the pathophysiology, the chronic nature and the potential risks that are commonly associated with this disease and its treatment, depending on disease severity. Above all, the safety and efficacy of the medicinal drug(s) to be used are of utmost importance, given the impact of non-virus-inactivated plasma-derived factor concentrates in the 1980s. As a consequence, the subsequent development and registration of recombinant clotting factors from mammalian, and recently, even human, cell cultures are seen by many as a breakthrough, although, regarding the product-type-dependent development of inhibitors in previously untreated patients, the discussion is still open. Clinical data for the humanised bispecific antibody Emicizumab in paediatric patients below 2 years of age without inhibitors who suffer from severe haemophilia A are currently limited.

Zusammenfassung

Mit der Zulassung der halbwertszeitverlängerten, rekombinanten Faktorkonzentrate, der Zulassung des nicht auf Faktor VIII Substitution basierenden Emicizumab und unter Berücksichtigung der zurzeit laufenden klinischen Studien ist die Beratung der Eltern eines Jungen mit neu diagnostizierter Hämophilie A nicht einfacher geworden. Die Eltern sollten über die Pathophysiologie der Erkrankung und - unter Berücksichtigung der Schwere der Erkrankung - die damit und mit der Behandlung verbundenen Risiken und den chronischen Verlauf informiert werden. Die Sicherheit und Wirksamkeit des zur Behandlung ausgewählten Medikaments ist von allergrößter Bedeutung, vor allem unter Berücksichtigung der Auswirkungen der Gabe nicht virusinaktivierter, plasmatischer Faktorenkonzentrate in den 80-er Jahren. Die darauffolgende Entwicklung rekombinanter Faktorenkonzentrate aus Säugetierzelllinien (und kürzlich aus humanen Zelllinien) wird von vielen als Durchbruch angesehen. Inwieweit dies auch für die Behandlung zuvor unbehandelter Patienten zutrifft und inwiefern es die Entwicklung von Hemmkörpern beeinflusst, ist noch nicht abschließend geklärt. Die Menge an klinischen Daten für den humanisierten, bispezifischen Antikörper Emicizumab für pädiatrische Patienten unter 2 Jahren, die an schwerer Hämophilie A ohne Inhibitoren leiden, ist zurzeit noch begrenzt.

Keywords

haemophilia A - parents - counselling

Schlüsselwörter

Hämophilie A - Eltern - Beratung

Authors' Contributions

K.K. wrote the manuscript, C.B. and M.O. have read and approved the final manuscript.


 

  • References

  • 1 Mannucci PM, Tuddenham EGD. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 2 Biggs R, Douglas AR, MacFarlane RG. et al. Christmas disease. A condition previously mistaken for haemophilia. BMJ 1952; 2 (4799): 1378-1382
    CrossrefPubMedGoogle Scholar
  • 3 Otto JC. An account of a hemorrhagic disposition existing in certain families. Med Phys J 1808; 20 (113) 69-72
    PubMedGoogle Scholar
  • 4 van Vulpen LFD, Holstein K, Martinoli C. Joint disease in haemophilia: pathophysiology, pain and imaging. Haemophilia 2018; 24 (Suppl. 06) 44-49
    CrossrefPubMedGoogle Scholar
  • 5 Carroll L, Benson G, Lambert J, Benmedjahed K, Zak M, Lee XY. Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom. Patient Prefer Adherence 2019; 13: 941-957
    CrossrefPubMedGoogle Scholar
  • 6 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
    CrossrefPubMedGoogle Scholar
  • 7 Hartl HK, Reitter S, Eidher U, Ramschak H, Ay C, Pabinger I. The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs. Haemophilia 2008; 14 (04) 703-708
    CrossrefPubMedGoogle Scholar
  • 8 Payal V, Sharma P, Goyal V, Jora R, Parakh M, Payal D. Clinical profile of hemophilia patients in Jodhpur Region. Asian J Transfus Sci 2016; 10 (01) 101-104
    CrossrefPubMedGoogle Scholar
  • 9 Zanon E, Pasca S. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus 2019; 17 (05) 378-384
    PubMedGoogle Scholar
  • 10 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. ; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (03) 560
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Santagostino E, Mancuso ME, Tripodi A. , et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8 (04) 737-743
    CrossrefPubMedGoogle Scholar
  • 12 Pavlova A, Oldenburg J. Defining severity of hemophilia: more than factor levels. Semin Thromb Hemost 2013; 39 (07) 702-710
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Zhou JY, Barnes RFW, Foster G, Iorio A, Cramer TJ, von Drygalski A. Joint bleeding tendencies in adult patients with hemophilia: It's not all pharmacokinetics. Clin Appl Thromb Hemost 2019; 25: 1-10
    PubMedGoogle Scholar
  • 14 den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17 (01) 41-44
    CrossrefPubMedGoogle Scholar
  • 15 The Hemophilia, von Willebrand Disease and Platelet Disorders Handbook. How hemophilia is inherited. Available at: https://www.hog.org/handbook/section/2/how-hemophilia-is-inherited . Assessed October 18, 2019
    PubMedGoogle Scholar
  • 16 Paroskie A, Oso O, Almassi B, DeBaun MR, Sidonio Jr RF. Both hemophilia health care providers and hemophilia a carriers report that carriers have excessive bleeding. J Pediatr Hematol Oncol 2014; 36 (04) e224-e230
    CrossrefPubMedGoogle Scholar
  • 17 Di Michele DM, Gibb C, Lefkowitz JM, Ni Q, Gerber LM, Ganguly A. Severe and moderate haemophilia A and B in US females. Haemophilia 2014; 20 (02) e136-e143
    CrossrefPubMedGoogle Scholar
  • 18 Radic CP, Rossetti LC, Abelleyro MM. , et al. Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation. J Thromb Haemost 2015; 13 (04) 530-539
    CrossrefPubMedGoogle Scholar
  • 19 Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia 2015; 21 (04) 550-557
    CrossrefPubMedGoogle Scholar
  • 20 Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie 2010; 30 (04) 207-211
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Gouw SC, van den Berg HM, Oldenburg J. , et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
    CrossrefPubMedGoogle Scholar
  • 22 MacLean PE, Fijnvandraat K, Beijlevelt M, Peters M. The impact of unaware carriership on the clinical presentation of haemophilia. Haemophilia 2004; 10 (05) 560-564
    CrossrefPubMedGoogle Scholar
  • 23 Witmer C, Presley R, Kulkarni R, Soucie JM, Manno CS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011; 152 (02) 211-216
    CrossrefPubMedGoogle Scholar
  • 24 Manco-Johnson MJ, Abshire TC, Shapiro AD. , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
    CrossrefPubMedGoogle Scholar
  • 25 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9 (04) 700-710
    CrossrefPubMedGoogle Scholar
  • 26 Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia a. Thromb Res 2018; 168: 20-27
    CrossrefPubMedGoogle Scholar
  • 27 Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost 2016; 116 (Suppl. 01) S10-S17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Annex I. Summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf . Assessed October 18, 2019
    PubMedGoogle Scholar
  • 29 Peyvandi F, Mannucci PM, Garagiola I. , et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374 (21) 2054-2064
    CrossrefPubMedGoogle Scholar
  • 30 Sande CM, Al-Huniti A, Ten Eyck P, Shrathkumar AA. Impact of the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study and its post hoc analyses on clinical practice in the United States: A survey of Haemophilia and Thrombosis Research Society members. Haemophilia 2019; 25 (05) 754-772
    PubMedGoogle Scholar
  • 31 Limperg PF, Haverman L, Beijlevelt M. , et al. Psychosocial care for children with haemophilia and their parents in the Netherlands. Haemophilia 2017; 23 (03) 362-369
    CrossrefPubMedGoogle Scholar
  • 32 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
    CrossrefPubMedGoogle Scholar
  • 33 Giangrande PLF, Peyvandi F, O'Mahony B. , et al. Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia 2017; 23 (03) 370-375
    CrossrefPubMedGoogle Scholar
  • 34 European Haemophilia Network. European guidelines for the certification of Haemophilia Centres. Available at: http://www.euhanet.org/docs/euhanet-european_guidelines_for_the_certification_of_haemophilia_centres_2013.pdf . Assessed October 18, 2019
    PubMed
  • 35 Executive Committee of the German Medical Association on the Recommendation of the Scientific Advisory Board. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives. 4th revised and updated ed. Berlin: German Medical Association; 2014. . Available at: https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/Querschnittsleitlinie_Gesamtdokument-englisch_07032011.pdf
    Google Scholar
  • 36 Thornburg CD. How I approach: previously untreated patients with severe congenital hemophilia A. Pediatr Blood Cancer 2018; 65 (12) e27466
    CrossrefPubMedGoogle Scholar
  • 37 Mannucci PM. Viral safety of coagulation factor concentrates: memoirs from an insider. J Thromb Haemost 2018; 16 (04) 630-633
    CrossrefPubMedGoogle Scholar
  • 38 Lassila R, Makris M. Safety surveillance in haemophilia and allied disorders. J Intern Med 2016; 279 (06) 515-523
    CrossrefPubMedGoogle Scholar
  • 39 National Hemophilia Foundation. Available at: https://www.hemophilia.org/sites/default/files/document/files/243SIPPET.pdf . Assessed October 18, 2019
    PubMed
  • 40 Dasgupta S, Repessé Y, Bayry J. , et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109 (02) 610-612
    CrossrefPubMedGoogle Scholar
  • 41 Mahlangu J, Cerquiera M, Srivastava A. Emerging therapies for haemophilia - Global perspective. Haemophilia 2018; 24 (Suppl. 06) 15-21
    PubMedGoogle Scholar
  • 42 Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood 2017; 130 (23) 2463-2468
    CrossrefPubMedGoogle Scholar
  • 43 Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Emicizumab for hemophilia A without inhibitors. Exp Rev Hematol 2019; 12 (07) 515-524
    CrossrefPubMedGoogle Scholar
  • 44 National Hemophilia Foundation. Available at: https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/Recommendation-on-the-Use-and-Management-of-Emicizumab-kxwh-Hemlibra-for-Hemophilia-A-with-and-without-Inhibitors . Assessed October 18, 2019
    PubMed
  • 45 Vepsäläinen K, Riikonen P, Lassila P. , et al. Long-term clinical and economic outcomes in previously untreated paediatric patients with severe haemophilia A: A nationwide real-world study with 700 person-years. Haemophilia 2018; 24 (03) 436-444
    CrossrefPubMedGoogle Scholar
  • 46 EMA. Assessment report. Available at: https://www.ema.europa.eu/en/documents/variation-report/hemlibra-h-c-4406-ii-0002-epar-assessment-report-variation_en.pdf . Assessed October 18, 2019
    PubMedGoogle Scholar
  • 47 Andrew M, Paes B, Milner R. , et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (01) 165-172
    CrossrefPubMedGoogle Scholar
  • 48 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of Emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Gouw SC, van der Bom JG, Marijke van den Berg H. for the CANAL study group. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
    CrossrefPubMedGoogle Scholar
  • 50 Pierce GF, Hart DP, Kaczmarek R. ; Committee on Coagulation Products Safety Supply, Access (CPSSA) of the World Federation of Hemophilia (WFH). Safety and efficacy of emicizumab and other novel agents in newborns and infants. Haemophilia 2019; 25 (05) e334-e335
    CrossrefPubMedGoogle Scholar